BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive LeukemiaMatthew S. Zabriskie, Thomas O’Hare, H. Jean Khoury et al.|Cancer Cell|2014Cited by 366
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibAndreas Hochhaus, H. Kantarjian, Michele Baccarani et al.|Leukemia|2008Cited by 354
Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients – An Observational StudyAndrew Ip, Stuart L. Goldberg, Donald A. Berry et al.|medRxiv|2020Cited by 69